Panzyga 10% (2500 mg) (Immune Globulin Subcutaneous (Human)-ifas, 10% Solution) 25 mL

Panzyga 10% (2500 mg) is an intravenous immune globulin therapy used to manage immune deficiencies and autoimmune conditions. It is primarily prescribed for primary immunodeficiency (PI), where it provides essential antibodies to enhance the immune response and prevent infections. Additionally, Panzyga is used for treating chronic inflammatory demyelinating polyneuropathy (CIDP), helping to improve muscle strength and mobility by modulating immune system activity. The treatment is pivotal in supporting patients with compromised immune functions and reducing the frequency and severity of infections.

Panzyga 10% (2500 mg) Immune Globulin Subcutaneous (Human) is used for the treatment of primary immunodeficiency (PI), boosting the immune system by providing necessary antibodies. It is also effective for chronic inflammatory demyelinating polyneuropathy (CIDP), helping to alleviate symptoms and improve muscle strength. Panzyga works by replacing or supplementing antibodies in patients with antibody deficiencies, thus offering protection against infections and supporting immune system function..

Panzyga 10% is a premium intravenous immunoglobulin (IVIG) therapy proudly presented by Octapharma. Intended for patients with compromised immune systems, Panzyga 10% provides critical passive immunity that helps to fight against infections. This innovative treatment comes in a 25 mL vial containing 2500 mg of purified immune globulin for subcutaneous or intravenous administration. Sourced from healthy human plasma, Panzyga 10% conforms to impeccable standards of safety and effectiveness, fortifying patients’ immune defense with unmatched reliability.

Product Details and Features

Concentration: 10% Immunoglobulin G (IgG) solution
Dosage Form: 2500 mg in 25 mL (equivalent to 10% solution)
Administration: Intravenous (IV) or Subcutaneous (SC)
Source: Human plasma
Purity: Maximum removal of IgA, less than 50 mcg/mL
Manufacturer: Octapharma, a leader in plasma derivatives

Mechanism of Action

Panzyga functions by delivering a high concentration of Immunoglobulin G (IgG) antibodies, collected from the plasma of healthy donors, directly into the patient's circulation. These antibodies are broad-spectrum in their ability to neutralize pathogens such as bacteria and viruses, as well as modulating the immune response, providing its therapeutic effect in a variety of conditions like primary immunodeficiencies and autoimmune disorders. 

Directions for Use

1. Administration: Panzyga 10% can be administered intravenously or subcutaneously, depending on the indication and patient need. 
2. Dosing: Dosage should be individualized based on patient condition, weight, and clinical response. 
3. Preparation: Visually inspect for particulate matter and discoloration. Do not shake.
4. Infusion Rate: Begin at a slow rate with a gradual increase contingent upon patient tolerance.

Consult healthcare professional guidelines for precise administration protocol.

Warnings

• Hypersensitivity: Be aware of potential allergic reactions; contraindicated in individuals with known hypersensitivity to immunoglobulin preparations.
  
• Blood Glucose Monitoring: This product may affect measurements; specifically use monitoring systems PCA or PDMS.
• Renal Dysfunction: Monitor renal function; cases of renal failure have been reported.
  
• Thrombosis: Exercise caution for individuals with a history of thrombosis. Ensure adequate hydration.

Side Effects

Common side effects may include:

• Mild to moderate headache
  
• Fatigue and fever
  
• Infusion site reactions like redness or swelling
  
• Nausea
  
• Hypertension

Rare but serious reactions might include:

• Anaphylaxis
  
• Thromboembolic events
  
• Hemolytic anemia
  
• Acute renal failure

 Disclaimer

This information serves as a summary of the essential aspects regarding the administration and potential impact of Panzyga 10%. Comprehensive prescribing information, direction from healthcare professionals, and personalized patient assessments are necessary to optimize the safe and effective use of Panzyga 10%.